×
182
Fashion Jobs
AQUAGENICS RESEARCH & DEVELOPMENT INDIA PVT. LTD.
Area Sales Manager
Permanent · Pune
MUTHOOT FINCORP
Area Manager
Permanent · Tiruchirappalli
INFINIX
National Sales Manager
Permanent · MUMBAI
1MG
Sales Manager - Diagnostics
Permanent · National Capital Region
DODLA DAIRY LIMITED
Area Sales Manager -Salem
Permanent · Salem
HALONIX TECHNOLOGIES PVT LTD
Area Sales Manager - Fans & Lighting / Retail Sales
Permanent · Ludhiana
BASIC ENTERPRISES PVT LTD
Area Sales Manager
Permanent · Mumbai
ZEE LABORATORIES LIMITED
Area Sales Manager / Regional Sales Manager
Permanent · Bhopal
CROSS COUNTRY INFOTECH
Production Manager
Permanent · Jodhpur
PROPERTYXPO.COM
Area Sales Manager| Real Estate Portfolio Management | Gurgaon
Permanent · Gurugram
RELIABLE CLOTHING PVT. LTD
Production Manager - Garment Manufacturing Export House
Permanent · Mumbai
HUMAN TOUCH
Sales Manager - Mumbai
Permanent · Mumbai
KAZO FASHION PRIVATE LIMITED
Garment Technician
Permanent · Noida
UMANO HEALTHCARE PRIVATE LIMITED
Regional Sales Manager / Area Sales Manager- (Pharma Sales) mp
Permanent · Bhopal
OLIVE GREEN CONSULTING LLP
Urgently Looking For Production Manager - Gurgaon
Permanent · Gurugram
MONEYWISE FINANCIAL SERVICES
Area Sales Manager || Nbfc (Lap / bl) - Delhi
Permanent · National Capital Region
MAGICBRICKS
Area Sales Manager
Permanent · Thane
KENT RO SYSTEMS
Corporate Sales Manager
Permanent · Chennai
RELAXO
Area Sales Manager
Permanent · Bargarh
OUTHOUSE JEWELLERY
E-Commerce Manager
Permanent · NOIDA
TOUCH MOBILES
Wanted Area Sales Manager - Touch Mobiles
Permanent · Khammam
GOKALDAS EXPORTS
Manager - Fabric Warehouse - Garments Background - Bhopal, mp
Permanent · Bhopal
By
Reuters
Published
Apr 20, 2009
Reading time
2 minutes
Share
Download
Download the article
Print
Click here to print
Text size
aA+ aA-

Glaxo to buy Stiefel for up to £2.5 billion

By
Reuters
Published
Apr 20, 2009

By Ben Hirschler

LONDON (Reuters) - GlaxoSmithKline (GSK.L), the world's second-largest drugmaker, has agreed to buy privately owned U.S. skincare specialist Stiefel Laboratories for up to $3.6 billion (2.5 billion pounds), the two companies said on Monday 20 April.


REUTERS/Toby Melville

The acquisition is the latest in a string of deals in the drugs sector, but is significantly smaller than recent mega-mergers, reflecting the group's declared focus on bolt-on buys to diversify its business.

Stiefel, part-owned by buyout firm Blackstone Group (BX.N), is the world's largest independent dermatology company, with a range of prescription and over-the-counter products.

It was put up for sale a month ago and attracted interest from a number of large pharmaceutical companies, including Novartis (NOVN.VX), Sanofi-Aventis (SASY.PA) and Johnson & Johnson (JNJ.N), according to people familiar with the matter.

Glaxo is paying $2.9 billion in cash for Stiefel and expects to assume $400 million of net debt. It will also make a potential further $300 million cash payment, depending on future performance.

That overall price is four times Stiefel's 2008 sales of around $900 million, but the group expects to extract substantial savings from merging the business, which will retain the Stiefel identity, into its structure.

Glaxo expects annual pre-tax cost savings of up to $240 million by 2012, with integration costs of some $325 million over the next three years.

Excluding integration costs, the deal will dilute Glaxo's earnings per share by less than 1 percent in 2009 and be 1-2 percent earnings accretive to EPS in 2010.The purchase will nearly treble the size of Glaxo's skincare business, giving it an 8 percent share of the global prescription dermatology market.

"It's an opportunity for Glaxo to strengthen its product mix," said Navid Malik, industry analyst at Matrix Corporate Capital. "This business should be very complementary."

The 160-year-old Stiefel is a maker of anti-itch creams, acne treatments and other skin treatments.

The purchase fits well with the strategy of Glaxo Chief Executive Andrew Witty, who wants to broaden the focus of the group away from its traditional reliance on small-molecule prescription medicines -- or pills.

Stiefel is controlled by the founding Stiefel family and current CEO Charles Stiefel will continue to lead the new business under the Glaxo umbrella after the deal closes in the third quarter of 2009.

Private-equity group Blackstone, which invested $500 million in the company in 2007, owns a substantial minority stake.

Glaxo shares were 0.4 percent higher at 10.42 pounds by 8:35 a.m., slightly outperforming a 0.2 percent gain in the European healthcare sector .SXDP.

(Editing by David Holmes and Jon Loades-Carter)

© Thomson Reuters 2022 All rights reserved.